The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
Lacosamide Injection is used to treat partial-onset seizures.
The drug will be manufactured at the group’s topical facility at Ahmedabad
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)